FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation

World Journal of Gastroenterology

Volumn 20, Issue 39, 2014, Pages 14430-14441

  Yao, Jun ^a   Zhou, Chun Suo ^a   Ma, Xiong ^b   Fu, Bai Qing ^a   Tao, Li Sheng ^a   Chen, Miao ^c   Xu, Ya Ping ^a  

^a JIANGSU UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c AFFILIATED PEOPLE S HOSPITAL OF JIANGSU UNIVERSITY   (China)

Author keywords

Farnesoid X receptor; GW4064; Lipopolysaccharide induced hepatic inflammation; Macrophage activation; Nonalcoholic fatty liver disease; Nonalcoholic fatty liver disease activity score

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CELL MARKER; CYTOKINE; DIMETHYL SULFOXIDE; ENDOTOXIN; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; FARNESOID X RECEPTOR; ANTIINFLAMMATORY AGENT; AUTACOID; CELL RECEPTOR; DIFFERENTIATION ANTIGEN; FARNESOID X-ACTIVATED RECEPTOR; ISOXAZOLE DERIVATIVE; LIPOPOLYSACCHARIDE; MONOCYTE-MACROPHAGE DIFFERENTIATION ANTIGEN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTERFERON GAMMA GENE; INTERLEUKIN 1BETA GENE; INTERLEUKIN 6 GENE; LIPID DIET; LIVER; MACROPHAGE ACTIVATION; MACROPHAGE CULTURE; MALE; MCP1 GENE; MOUSE; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; NONHUMAN; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; TOXIC HEPATITIS; AGONISTS; ANIMAL; C57BL MOUSE; CELL LINE; CHEMICALLY INDUCED; DISEASE MODEL; DOWN REGULATION; DRUG EFFECTS; IMMUNOLOGY; MACROPHAGE; METABOLISM; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ADULT; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIGENS, DIFFERENTIATION; APOPTOSIS; CELL LINE; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; HUMANS; INFLAMMATION MEDIATORS; ISOXAZOLES; LIPOPOLYSACCHARIDES; LIVER; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MICE, INBRED C57BL; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84910108693     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i39.14430     Document Type: Article

References (36)

1. Bechmann LP, Kocabayoglu P, Sowa JP, Sydor S, Best J, Schlattjan M, Beilfuss A, Schmitt J, Hannivoort RA, Kilicarslan A, Rust C, Berr F, Tschopp O, Gerken G, Friedman SL, Geier A, Canbay A. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology 2013; 57: 1394-1406 [PMID: 23299969 DOI: 10.1002/hep.26225]
2. Puri P, Wiest MM, Cheung O, Mirshahi F, Sargeant C, Min HK, Contos MJ, Sterling RK, Fuchs M, Zhou H, Watkins SM, Sanyal AJ. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 2009; 50: 1827-1838 [PMID: 19937697 DOI: 10.1002/hep.23229]
3. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997; 126: 137-145 [PMID: 9005748 DOI: 10.7326/0003-4819-126-2]
4. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011; 332: 1519-1523 [PMID: 21700865 DOI: 10.1126/science.1204265]
5. Li Y, Jadhav K, Zhang Y. Bile acid receptors in non-alcoholic fatty liver disease. Biochem Pharmacol 2013; 86: 1517-1524 [PMID: 23988487 DOI: 10.1016/j.bcp.2013.08.015]
6. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010; 52: 774-788 [PMID: 20683968 DOI: 10.1002/hep.23719]
7. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-455 [PMID: 10569299]
8. Hebbard L, George J. Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2011; 8: 35-44 [PMID: 21119613]
9. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: 1441-1447 [PMID: 18390575 DOI: 10.1136/gut.2007.146019]
10. Bhargava P, Li C, Stanya KJ, Jacobi D, Dai L, Liu S, Gangl MR, Harn DA, Lee CH. Immunomodulatory glycan LNFPIII alleviates hepatosteatosis and insulin resistance through direct and indirect control of metabolic pathways. Nat Med 2012; 18: 1665-1672 [PMID: 23104131 DOI: 10.1038/nm.2962]
11. Chen Y, Song X, Valanejad L, Vasilenko A, More V, Qiu X, Chen W, Lai Y, Slitt A, Stoner M, Yan B, Deng R. Bile salt export pump is dysregulated with altered farnesoid X receptor isoform expression in patients with hepatocellular carcinoma. Hepatology 2013; 57: 1530-1541 [PMID: 23213087 DOI: 10.1002/hep.26187]
12. Modica S, Petruzzelli M, Bellafante E, Murzilli S, Salvatore L, Celli N, Di Tullio G, Palasciano G, Moustafa T, Halilbasic E, Trauner M, Moschetta A. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 2012; 142: 355-365.e1-e4 [PMID: 22057115 DOI: 10.1053/j.gastro.2011.10.028]
13. Chen F, Ma L, Dawson PA, Sinal CJ, Sehayek E, Gonzalez FJ, Breslow J, Ananthanarayanan M, Shneider BL. Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter. J Biol Chem 2003; 278: 19909-19916 [PMID: 12456679 DOI: 10.1074/jbc.M207903200]
14. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009; 89: 147-191 [PMID: 19126757 DOI: 10.1152/physrev.00010.2008]
15. Claudel T, Zollner G, Wagner M, Trauner M. Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease. Biochim Biophys Acta 2011; 1812: 867-878 [PMID: 21194565 DOI: 10.1016/j.bbadis.2010.12.021]
16. Zollner G, Marschall HU, Wagner M, Trauner M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharm 2006; 3: 231-251 [PMID: 16749856 DOI: 10.1021/mp060010s]
17. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, Moore DD, Auwerx J. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004; 113: 1408-1418 [PMID: 15146238 DOI: 10.1172/JCI21025]
18. Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006; 116: 1102-1109 [PMID: 16557297 DOI: 10.1172/JCI25604]
19. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM, Edwards PA. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 2006; 103: 1006-1011 [PMID: 16410358 DOI: 10.1073/pnas.0506982103]
20. Stayrook KR, Bramlett KS, Savkur RS, Ficorilli J, Cook T, Christe ME, Michael LF, Burris TP. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 2005; 146: 984-991 [PMID: 15564327]
21. Prawitt J, Abdelkarim M, Stroeve JH, Popescu I, Duez H, Velagapudi VR, Dumont J, Bouchaert E, van Dijk TH, Lucas A, Dorchies E, Daoudi M, Lestavel S, Gonzalez FJ, Oresic M, Cariou B, Kuipers F, Caron S, Staels B. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 2011; 60: 1861-1871 [PMID: 21593203 DOI: 10.2337/db11-0030]
22. Zhang Y, Ge X, Heemstra LA, Chen WD, Xu J, Smith JL, Ma H, Kasim N, Edwards PA, Novak CM. Loss of FXR protects against diet-induced obesity and accelerates liver carcinogenesis in ob/ob mice. Mol Endocrinol 2012; 26: 272-280 [PMID: 22261820 DOI: 10.1210/me.2011-1157]
23. Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol 2009; 51: 212-223 [PMID: 19447517 DOI: 10.1016/j.jhep.2009.03.008]
24. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, Desimone C, Song XY, Diehl AM. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 343-350 [PMID: 12540784 DOI: 10.1053/jhep.2003.50048]
25. Si Y, Tsou CL, Croft K, Charo IF. CCR2 mediates hematopoietic stem and progenitor cell trafficking to sites of inflammation in mice. J Clin Invest 2010; 120: 1192-1203 [PMID: 20234092 DOI: 10.1172/JCI40310]
26. Bouwens L, Baekeland M, De Zanger R, Wisse E. Quantitation, tissue distribution and proliferation kinetics of Kupffer cells in normal rat liver. Hepatology 1986; 6: 718-722 [PMID: 3733004]
27. Bogdanos DP, Gao B, Gershwin ME. Liver immunology. Compr Physiol 2013; 3: 567-598 [PMID: 23720323 DOI: 10.1002/cphy.c120011]
28. Ioannou GN. Implications of elevated serum alanine aminotransferase levels: think outside the liver. Gastroenterology 2008; 135: 1851-1854 [PMID: 19007778 DOI: 10.1053/j.gastro.2008.11.005]
29. Mylonas KJ, Hoeve MA, MacDonald AS, Allen JE. Alternative activation of macrophages by filarial nematodes is MyD88-independent. Immunobiology 2013; 218: 570-578 [PMID: 22884360 DOI: 10.1016/j.imbio.2012.07.006]
30. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010; 11: 889-896 [PMID: 20856220 DOI: 10.1038/ni.1937]
31. McMahan RH, Wang XX, Cheng LL, Krisko T, Smith M, El Kasmi K, Pruzanski M, Adorini L, Golden-Mason L, Levi M, Rosen HR. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J Biol Chem 2013; 288: 11761-11770 [PMID: 23460643 DOI: 10.1074/jbc.M112.446575]
32. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008; 7: 678-693 [PMID: 18670431 DOI: 10.1038/nrd2619]
33. Lee J, Seok S, Yu P, Kim K, Smith Z, Rivas-Astroza M, Zhong S, Kemper JK. Genomic analysis of hepatic farnesoid X receptor binding sites reveals altered binding in obesity and direct gene repression by farnesoid X receptor in mice. Hepatology 2012; 56: 108-117 [PMID: 22278336 DOI: 10.1002/hep.25609]
34. Ma Y, Huang Y, Yan L, Gao M, Liu D. Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance. Pharm Res 2013; 30: 1447-1457 [PMID: 23371517 DOI: 10.1007/s11095-013-0986-7]
35. Lu Y, Ma Z, Zhang Z, Xiong X, Wang X, Zhang H, Shi G, Xia X, Ning G, Li X. Yin Yang 1 promotes hepatic steatosis through repression of farnesoid X receptor in obese mice. Gut 2014; 63: 170-178 [PMID: 23348961 DOI: 10.1136/gutjnl-2012-303150]
36. Fiorucci S, Rizzo G, Donini A, Distrutti E, Santucci L. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol Med 2007; 13: 298-309 [PMID: 17588816 DOI: 10.1016/j.molmed.2007.06.001]